Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2016-08-29 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
以自筹资金预先投入募集资金投资项目的专项鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项鉴证报告" (Special Verification Report) related to the use of self-raised funds pre-invested in fundraising projects by 山东瑞康医药股份有限公司. It is issued by a certified public accounting firm (北京天圆全会计师事务所) and includes an auditor's opinion on the company's special statement about the pre-investment of self-raised funds. The document contains detailed audit procedures, management responsibilities, and an auditor's conclusion, which aligns with an audit or assurance report rather than a full annual or interim financial report. It is not a full Annual Report (10-K) or Interim Report (IR) because it focuses specifically on the verification of a particular financial matter (pre-investment of funds) and is issued as a standalone audit assurance document. The document length (9165 characters) and content indicate it is a full report, not a brief announcement or certification letter. Therefore, the most appropriate classification is Audit Report / Information (AR). FY 2016
2016-08-29 Chinese
独立董事候选人声明（权玉华）
Board/Management Information Classification · 95% confidence The document is a public declaration by an independent director candidate of Shandong Ruikang Pharmaceutical Co., Ltd. It details the candidate's qualifications, compliance with regulatory requirements, and independence criteria. There is no financial data, no report or announcement of financial results, no voting results, no management changes, or other corporate actions. The document is a formal statement related to board/management information, specifically about the candidacy and qualifications of a board member. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short and focused solely on the candidate's declaration, confirming it is not a full report or announcement of a report.
2016-08-29 Chinese
关于转让应收账款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the transfer of accounts receivable by Shandong Ruikang Pharmaceutical Co., Ltd. It details the transaction overview, parties involved, and the impact on the company. The document is relatively short (1529 characters) and focuses on a specific financing transaction involving asset-backed securitization. It does not contain financial statements or detailed financial results, nor is it a report or presentation. It is an update on a capital/financing activity, specifically the transfer of receivables to set up a financing plan. Therefore, it fits best under the category 'Capital/Financing Update' (CAP).
2016-08-29 Chinese
关于以募集资金置换预先投入募集资金投资项目的自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shandong Ruikang Pharmaceutical Co., Ltd. regarding the use of raised funds to replace self-raised funds previously invested in a fundraising project. It details the non-public issuance of shares, the amount raised, the investment project, and the specific fund replacement plan. It includes opinions from accountants, independent directors, the supervisory board, and the sponsoring institution. The document is relatively short (2861 characters) and primarily serves as a formal announcement of a financing and fund usage update rather than a full financial report or audit report. It does not contain comprehensive financial statements or detailed financial analysis. The content fits best under Capital/Financing Update (CAP) as it relates to fundraising and capital usage updates.
2016-08-29 Chinese
国金证券股份有限公司关于公司使用部分闲置募集资金暂时补充流动资金事项的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from Guojin Securities Co., Ltd. regarding Shandong Ruikang Pharmaceutical Co., Ltd.'s use of part of idle raised funds to temporarily supplement working capital. It references regulatory approvals, fundraising details, and compliance with securities regulations. The document is a formal verification or audit opinion on the use of raised funds, not a full financial report or earnings release. It does not contain comprehensive financial statements or management discussion but focuses on compliance and verification of fund usage. This fits the category of an Audit Report / Information (AR), which includes audit reports and verification opinions related to accounting and regulatory compliance, excluding full annual or interim reports. The document length is under 5,000 characters, but it is not merely an announcement of a report; it contains substantive verification content. Therefore, the appropriate classification is AR with high confidence. FY 2016
2016-08-29 Chinese
独立董事提名人声明
Board/Management Information Classification · 95% confidence The document is a public statement from the board of directors of Shandong Ruikang Pharmaceutical Co., Ltd. regarding the nomination of independent directors for the company's third board. It details the qualifications, compliance with laws and regulations, and independence criteria of the nominees. There is no financial data, no report of voting results, no financial performance information, and no mention of any report publication. The document is a formal announcement related to board/management information, specifically about director nominations. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 2502 characters, which is relatively short but contains substantive content about board nominations, not just a brief announcement or certification.
2016-08-29 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.